Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roanne Segal

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 23, 2014
Physical functioning for prostate healthRoanne Segal
Urologic Oncology|January 18, 2006
Surveillance programs for stage I nonseminomatous germ cell tumors of the testisRoanne Segal
BMJ Case Reports|November 6, 2012
Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature reviewJennifer Croke, Eugene Leung, Roanne Segal, et al.
BJU International|August 18, 2005
Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II studyShawn Malone, Gad Perry, Roanne Segal, et al.
The Journal of Urology|January 10, 2004
Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysisEric Winquist, Tricia S Kirchner, Roanne Segal, et al.
Cureus|September 20, 2017
Complete Remission in Locally Advanced Breast Cancer: What Comprehensive Multi-Modality Treatment Has to Offer in Sub-Saharan AfricaGaurav Bhattacharya, Susan C Msadabwe-Chikuni, Roanne Segal, et al.
The Canadian Journal of Urology|November 15, 2002
Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guidelineRoanne Segal, Eric Winquist, Himu Lukka, et al.
Urologic Oncology|May 5, 2005
A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approachE Choan, Roanne Segal, Derek Jonker, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2007
Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcomeShawn Malone, Gad Perry, Libni Eapen, et al.
Cancer Chemotherapy and Pharmacology|July 14, 2009
A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancerSusan F Dent, Stan Gertler, Shailendra Verma, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 23, 2014
Physical functioning for prostate healthRoanne Segal
Urologic Oncology|January 18, 2006
Surveillance programs for stage I nonseminomatous germ cell tumors of the testisRoanne Segal
BMJ Case Reports|November 6, 2012
Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature reviewJennifer Croke, Eugene Leung, Roanne Segal, et al.
BJU International|August 18, 2005
Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II studyShawn Malone, Gad Perry, Roanne Segal, et al.
The Journal of Urology|January 10, 2004
Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysisEric Winquist, Tricia S Kirchner, Roanne Segal, et al.
Cureus|September 20, 2017
Complete Remission in Locally Advanced Breast Cancer: What Comprehensive Multi-Modality Treatment Has to Offer in Sub-Saharan AfricaGaurav Bhattacharya, Susan C Msadabwe-Chikuni, Roanne Segal, et al.
The Canadian Journal of Urology|November 15, 2002
Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guidelineRoanne Segal, Eric Winquist, Himu Lukka, et al.
Urologic Oncology|May 5, 2005
A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approachE Choan, Roanne Segal, Derek Jonker, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2007
Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcomeShawn Malone, Gad Perry, Libni Eapen, et al.
Cancer Chemotherapy and Pharmacology|July 14, 2009
A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancerSusan F Dent, Stan Gertler, Shailendra Verma, et al.
Pageof 3